サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1405098

加齢黄斑変性-主要7ヶ国市場の薬剤予測と市場分析- 最新情報

Age-Related Macular Degeneration - Seven-Market Drug Forecast and Market Analysis - Update
出版日: | 発行: GlobalData | ページ情報: 英文 115 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
加齢黄斑変性-主要7ヶ国市場の薬剤予測と市場分析- 最新情報
出版日: 2023年12月22日
発行: GlobalData
ページ情報: 英文 115 Pages
納期: 即納可能 即納可能とは
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

加齢黄斑変性薬物療法の市場規模は、2021年から2031年にかけて大幅な伸びが見込まれ、予測期間全体の年間平均成長率（CAGR）は14.1%に達すると見込まれています。2021年の加齢黄斑変性市場規模は主要7ヶ国市場全体で74億米ドルとなっており、米国が市場の51.7%を占めています。欧州5大市場（5EU）（フランス、ドイツ、イタリア、スペイン、英国）は世界の加齢黄斑変性市場の40.8%を占め、推定市場規模は30億米ドル、日本の加齢黄斑変性市場は2021年に5億5,080万米ドルと推定され、市場の7.5%を占めています。

予測期間中、加齢黄斑変性市場は2031年には275億米ドル規模に成長すると予測され、米国は世界市場の72.1%を占め、市場規模は198億米ドルに達すると予測されます。米国はCAGR 18.0%でこの期間に最も急成長し、EUはCAGR 9.0%で成長し、2031年の市場規模は71億米ドルに達すると予測されます。日本は、予測期間中のCAGRが0.4%と主要7ヶ国市場の中で最も成長が鈍化し、2031年の市場価値は5億7,090万米ドルになると予測されます。

当レポートでは、主要7ヶ国（米国、フランス、ドイツ、イタリア、スペイン、英国、日本）の加齢黄斑変性市場について調査し、市場の概要とともに、パイプライン動向、2021年～2031年の予測、市場に参入する企業の動向などを提供します。

目次

第1章 加齢黄斑変性症：エグゼクティブサマリー

第2章 イントロダクション

第3章 病気の概要

  • 病因学と病態生理学
    • 概要
    • 病因
    • 病態生理学
  • 分類または病期分類システム

第4章 疫学

  • 病気の背景
  • 危険因子と併存疾患
  • 世界の市場実績
  • 主要7ヶ国市場予測調査手法
  • 加齢黄斑変性の疫学予測（2021～31年）
  • 議論

第5章 疾病管理

  • 診断と治療の概要
  • 疾病管理に関するKOLの洞察

第6章 競争力の評価

第7章 アンメットニーズと機会の評価

  • 概要
  • 長時間作用型抗VEGF療法
  • GAの治療
  • 専門医の有無やアクセスのしやすさ、患者の待ち時間
  • 侵襲性の低い薬剤製剤
  • 患者の早期診断と加齢黄斑変性に対する認識の向上

第8章 研究開発戦略

  • 概要
  • 臨床試験の設計

第9章 パイプラインの評価

  • 概要
  • 臨床開発中の有望な薬剤

第10章 パイプラインの評価分析

  • 概要
  • 競争力評価

第11章 現在および将来の参入企業

第12章 市場の展望

  • 世界市場
  • 米国
  • 欧州5ヶ国
  • 日本

第13章 付録

図表

List of Tables

List of Tables

  • Table 1: AMD: key metrics in the 7MM
  • Table 2: Biological pathways associated with AMD risk genes
  • Table 3: The four-stage AREDS classification of AMD
  • Table 4: Symptoms of AMD
  • Table 5: Risk Factors and Comorbid Conditions Associated with AMD
  • Table 6: Treatment guidelines for AMD
  • Table 7: Top 10 deals by value, 2016-21
  • Table 8: AMD market - global drivers and barriers, 2021-31
  • Table 9: Key events impacting sales for AMD in the US, 2021-31
  • Table 10: AMD market - drivers and barriers in the US, 2021-31
  • Table 11: Key events impacting sales for AMD in the 5EU, 2021-31
  • Table 12: AMD market - drivers and barriers in the 5EU, 2021-31
  • Table 13: Key events impacting sales for AMD in Japan, 2021-31
  • Table 14: AMD market - drivers and barriers in Japan, 2021-31
  • Table 15: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figures

List of Figures

  • Figure 1: Global sales forecast by country for AMD in 2021 and 2031
  • Figure 2: Analysis of the company portfolio gap in AMD during the forecast period
  • Figure 3: Competitive assessment of recently approved and late-stage pipeline agents that GlobalData expects to be licensed for the treatment of wAMD and GA during the forecast period
  • Figure 4: Comparison of the eye under normal vision and severe vision loss due to AMD
  • Figure 5: 7MM, Total Prevalence of AMD, Men and Women, Ages ≥50 Years, %, 2021
  • Figure 6: 7MM, Diagnosed Prevalence of AMD, Men and Women, Ages ≥50 Years, 2021
  • Figure 7: 7MM, sources used and not used to forecast the total prevalent cases of AMD, early AMD, late AMD, late dry AMD, and wet AMD
  • Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of AMD, early AMD, late AMD, late dry AMD, and wet AMD
  • Figure 9: 7MM, total prevalent cases of AMD, both sexes, ages ≥50 years, N, 2021
  • Figure 10: 7MM, total prevalent cases of AMD by age, both sexes, N, 2021
  • Figure 11: 7MM, total prevalent cases of AMD, by sex, ages ≥50 years, N, 2021
  • Figure 12: 7MM, total prevalent cases of early AMD, both sexes, ages ≥50 years, N, 2021
  • Figure 13: 7MM, total prevalent cases of late AMD, both sexes, ages ≥50 years, N, 2021
  • Figure 14: 7MM, total prevalent cases of late dry AMD, both sexes, ages ≥50 years, N, 2021
  • Figure 15: 7MM, total prevalent cases of wet AMD, both sexes, ages ≥50 years, N, 2021
  • Figure 16: 7MM, diagnosed prevalent cases of AMD, both sexes, ages ≥50 years, N, 2021
  • Figure 17: 7MM, diagnosed prevalent cases of AMD by age, both sexes, N, 2021
  • Figure 18: 7MM, diagnosed prevalent cases of AMD, by sex, ages ≥50 years, N, 2021
  • Figure 19: 7MM, Diagnosed prevalent cases of early AMD, both sexes, ages ≥50 years, N, 2021
  • Figure 20: 7MM, diagnosed prevalent cases of late AMD, both sexes, ages ≥50 years, N, 2021
  • Figure 21: 7MM, diagnosed prevalent cases of late dry AMD, both sexes, ages ≥50 years, N, 2021
  • Figure 22: 7MM, diagnosed prevalent cases of wet AMD, both sexes, ages ≥50 years, N, 2021
  • Figure 23: Amsler grid, as viewed by patients with normal vision and with wAMD
  • Figure 24: Unmet needs and opportunities in AMD
  • Figure 25: Overview of the development pipeline in AMD
  • Figure 26: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for AMD in the 7MM during the forecast period
  • Figure 27: Competitive assessment of recently approved agents and late-stage pipeline agents that GlobalData expects to be licensed for the treatment of wAMD and GA during the forecast period
  • Figure 28: Competitive assessment of the pipeline drugs benchmarked against the standard of care, Eylea
  • Figure 29: Analysis of the company portfolio gap in AMD during the forecast period
  • Figure 30: Global (7MM) sales forecast by country for AMD in 2021 and 2031
  • Figure 31: Sales forecast by disease subtype for AMD in the US in 2031
  • Figure 32: Sales forecast for GA in the US in 2031
  • Figure 33: Sales forecast by class for wAMD in the US in 2021 and 2031
  • Figure 34: Sales forecast by disease subtype in the 5EU in 2031
  • Figure 35: Sales forecast by class for wAMD in the 5EU in 2021 and 2031
  • Figure 36: Sales forecast by class for wAMD in Japan in 2021 and 2031
目次

Abstract

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Age-Related Macular Degeneration (AMD) market through 2031.

Drug sales in the AMD pharmacotherapy market are expected to grow by a significant margin between 2021 and 2031, with an overall compound annual growth rate (CAGR) of 14.1% over the forecast period. In 2021, GlobalData estimated the total AMD market to be valued at $7.4 billion across the 7MM, with the US accounting for 51.7% of the market. The five major European markets (5EU) (France, Germany, Italy, Spain, and UK) accounted for 40.8% of the global AMD market with an estimated value of $3.0 billion, and Japan's AMD market was estimated to be $550.8 million in 2021, accounting for 7.5% of the market.

Over the forecast period, the AMD market is anticipated to grow to a value of $27.5 billion in 2031, with the US anticipated to account for 72.1% of the global market and a market value of $19.8 billion. The US is anticipated to experience the fastest growth during this period with a CAGR of 18.0%, while the 5EU is anticipated to grow at a CAGR of 9.0% to reach a market value of $7.1 billion in 2031. Japan is anticipated to witness the slowest growth among the 7MM with a CAGR of 0.4% during the forecast period and a market value of $570.9 million in 2031.

Key Highlights

Report deliverables include a Pdf report and an Excel-based forecast model

Forecast includes the 7 major markets (7MM)

Forecast covers the period 2021-2031.

2021 base year sales within the AMD market are approximately $7.4 billion across the 7MM detailed in this report. GlobalData estimates that the AMD market will grow at a compound annual growth rate (CAGR) of 14.1% to reach $27.5 billion by the end of the forecast period.

Scope

  • Overview of AMD, including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized AMD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the AMD market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for AMD. The most promising candidates in late-stage development are profiled.
  • Analysis of the current and future market competition in the 7MM AMD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the 7MM AMD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM VTE therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

  • About GlobalData

1 Age-Related Macular Degeneration: Executive Summary

  • 1.1 AMD market will grow significantly during the forecast period, reaching sales of $27.5 billion in 2031
  • 1.2 Development of cell-based and gene therapies represent a new paradigm for AMD
  • 1.3 Reducing treatment burden is an important unmet need for wet AMD
  • 1.4 Treatment for geographic atrophy and dry AMD represent an important unmet need for AMD
  • 1.5 Late-stage pipeline therapies are anticipated to drive growth in the AMD market
  • 1.6 What do physicians think?

2 Introduction

  • 2.1 Catalyst
  • 2.2 Related reports
  • 2.3 Upcoming reports

3 Disease Overview

  • 3.1 Etiology and pathophysiology
    • 3.1.1 Overview
    • 3.1.2 Etiology
    • 3.1.3 Pathophysiology
  • 3.2 Classification or staging systems

4 Epidemiology

  • 4.1 Disease background
  • 4.2 Risk factors and comorbidities
  • 4.3 Global and historical trends
  • 4.4 7MM forecast methodology
    • 4.4.1 Sources
    • 4.4.2 Forecast assumptions and methods
    • 4.4.3 Forecast assumptions and methods: total prevalent cases of AMD, early AMD, late AMD, late dry AMD, and wet AMD
    • 4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of AMD, early AMD, late AMD, late dry AMD, and wet AMD
  • 4.5 Epidemiological forecast for AMD (2021-31)
    • 4.5.1 Total prevalent cases of AMD
    • 4.5.2 Age-specific total prevalent cases of AMD
    • 4.5.3 Sex-specific total prevalent cases of AMD
    • 4.5.4 Total prevalent cases of early AMD
    • 4.5.5 Total prevalent cases of late AMD
    • 4.5.6 Total prevalent cases of late dry AMD
    • 4.5.7 Total prevalent cases of wet AMD
    • 4.5.8 Diagnosed prevalent cases of AMD
    • 4.5.9 Age-specific diagnosed prevalent cases of AMD
    • 4.5.10 Sex-specific diagnosed prevalent cases of AMD
    • 4.5.11 Diagnosed prevalent cases of early AMD
    • 4.5.12 Diagnosed prevalent cases of late AMD
    • 4.5.13 Diagnosed prevalent cases of late dry AMD
    • 4.5.14 Diagnosed prevalent cases of wet AMD
  • 4.6 Discussion
    • 4.6.1 Epidemiological forecast insight
    • 4.6.2 COVID-19 impact
    • 4.6.3 Limitations of the analysis
    • 4.6.4 Strengths of the analysis

5 Disease Management

  • 5.1 Diagnosis and treatment overview
  • 5.2 KOL Insights on Disease Management

6 Competitive Assessment

  • 6.1 Overview

7 Unmet Needs and Opportunity Assessment

  • 7.1 Overview
  • 7.2 Longer-acting anti-VEGF therapies
  • 7.3 Treatment for GA
  • 7.4 Availability or accessibility of specialists and patient wait times
  • 7.5 Less invasive drug formulations
  • 7.6 Early diagnosis of patients and increasing awareness of AMD

8 R&D Strategies

  • 8.1 Overview
    • 8.1.1 Focus on the development of longer-acting therapies
    • 8.1.2 Diversifying into gene therapies for AMD
    • 8.1.3 Development of cell therapies for AMD
  • 8.2 Clinical trials design
    • 8.2.1 Consideration of endpoints for the whole spectrum of AMD

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

  • 10.1 Overview
  • 10.2 Competitive assessment

11 Current and Future Players

  • 11.1 Overview
  • 11.2 Deal-making trends

12 Market Outlook

  • 12.1 Global markets
    • 12.1.1 Forecast
    • 12.1.2 Drivers and barriers - global issues
  • 12.2 US
    • 12.2.1 Forecast
    • 12.2.2 Key events
    • 12.2.3 Drivers and barriers
  • 12.3 5EU
    • 12.3.1 Forecast
    • 12.3.2 Key events
    • 12.3.3 Drivers and barriers
  • 12.4 Japan
    • 12.4.1 Forecast
    • 12.4.2 Key events
    • 12.4.3 Drivers and barriers

13 Appendix

  • 13.1 Bibliography
  • 13.2 Abbreviations
  • 13.3 Methodology
    • 13.3.1 Forecasting methodology
  • 13.4 Primary research - KOLs interviewed for this report
    • 13.4.1 KOLs
  • 13.5 Primary research - prescriber survey
  • 13.6 About the authors
    • 13.6.1 Analyst
    • 13.6.2 Therapy Area Director
    • 13.6.3 Epidemiologist
    • 13.6.4 Managing Epidemiologist/Reviewers
    • 13.6.5 Global Director of Therapy Analysis and Epidemiology
  • Contact Us